Table 3.

Univariate and multivariate analysis of progression-free survival

Variables		Univariate		P	Multivariatea		P
		HR	95% CI		HR	95% CI
Multiparous	Yes	0.32	0.15–0.67	0.024
Nulliparous	No	1
Diameter	≥10	0.26	0.09–0.70	0.0076
	<10	1
Histology	Serous	1
	Mucinous	0.41	0.18–0.95	0.0375
	Endometrioid	0.64	0.19–2.19	0.4808
Micropapillary	Yes	3.88	1.76–8.52	0.0008
	No	1
Stage	II & III	2.55	1.10–5.91	0.0295
	I	1
Fertility preserving surgery
USO		1.6	0.59–4.33	0.3553	1.26	0.37–4.08	0.7395
USO + CC		5.74	2.10–15.67	0.0007	2.72	0.65–11.38	0.1719
BC		5.89	2.25–14.42	0.0003	3.95	1.22–12.85	0.0223
Radical surgery		1
Invasive implant	Yes	4.87	1.67–14.20	0.0038	10.38	2.21–48.69	0.0030
	No	1
Lymphadenectomy	Yes	0.44	0.21–0.94	0.0328	0.26	0.09–0.75	0.0129
	No	1
Pelvic lymph node metastasis	Yes	4.34	1.21–15.67	0.0246
	No	1
Para-aortic lymph node metastasis	Yes	17.34	1.80–167.50	0.0137
	No	1
Chemotherapy	Yes	2.72	1.20–6.19	0.0164
	No
Restaging	Yes	9.8	3.96–23.78	<0.0001
	No

USO unilateral salpingo-oophorectom, USO + CC unilateral salpingo-oophorectomy plus contralateral cystectomy, BC bilateral cystectomy

^aMultivariate model was built after controlling for tumor histology and stage